Skip to content
AnalystLens

Fortive 8-K Report, Executive Changes (Feb 26, 2025)

Reports
Leadership Changes
Filing Date
Filed February 26, 2025
Period End
February 26, 2025
Security
FTV
In the record · 2016–202610-K1010-Q328-K120

FTV filed 10 annual reports (10-K), 32 quarterly reports (10-Q) and 120 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’18Oct ’18
  2. Deal closed8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Dec ’22Dec ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed February 26, 2025. Cited figures are marked; the original filing is the authoritative source.

Fortive Corporation disclosed in a Form 8-K dated February 26, 2025 that its Board of Directors increased the size of the Board from nine to ten members, effective that day.

The Board appointed Gregory J. Moore, M.D., Ph.D., as a director to fill the new seat. His term runs from February 26, 2025 until the 2025 Annual Meeting of Shareholders, and until his successor is duly elected and qualified.

The Board also appointed Dr. Moore to its Compensation Committee and Nominating and Governance Committee. As a non-employee director, he will receive the same compensation as the Company's other non-employee directors, as described in Exhibit 10.16 to the Company's Form 10-K for the fiscal year ended December 31, 2023. He has also entered into the Company's standard indemnification agreement, the form of which was filed as Exhibit 10.10 to Amendment No. 2 to the Company's Form 10 registration statement filed on April 7, 2016.

The Board determined that Dr. Moore is independent under the New York Stock Exchange listing standards. The filing states that there is no arrangement or understanding between Dr. Moore and any other person under which he was selected as a director, and that there are no transactions involving him requiring disclosure under Item 404(a) of Regulation S-K.

Key Highlights

  1. The Board expanded from nine to ten members, effective February 26, 2025.
  2. Gregory J. Moore, M.D., Ph.D., was appointed as a director effective February 26, 2025.
  3. Dr. Moore's term runs until the 2025 Annual Meeting of Shareholders, or until a successor is duly elected and qualified.
  4. Dr. Moore was appointed to the Compensation Committee and the Nominating and Governance Committee.
  5. As a non-employee director, Dr. Moore receives the same compensation as other non-employee directors, as disclosed in the Company's Form 10-K for fiscal 2023.
  6. The Board determined Dr. Moore is independent under New York Stock Exchange listing standards.
  7. Dr. Moore has entered into the Company's standard indemnification agreement, and the filing reports no related-party transactions requiring disclosure under Item 404(a).

Frequently Asked Questions

  1. Who was appointed to Fortive's Board of Directors?

    Gregory J. Moore, M.D., Ph.D., was appointed to the Board effective February 26, 2025, when the Board also increased its size from nine to ten members.

  2. How long will Dr. Moore serve on the Board?

    His term begins February 26, 2025 and expires at the 2025 Annual Meeting of Shareholders, or when his successor is duly elected and qualified.

  3. What committees will Dr. Moore serve on?

    He was appointed to the Compensation Committee and the Nominating and Governance Committee of the Board.

  4. How will Dr. Moore be compensated?

    As a non-employee director, he will receive the same compensation paid to the Company's other non-employee directors, as disclosed in Exhibit 10.16 to the Company's Form 10-K for the fiscal year ended December 31, 2023.

  5. Is Dr. Moore considered independent?

    Yes. The Board determined that Dr. Moore is independent within the meaning of the New York Stock Exchange listing standards.